Controlled dangerous substances; exempting certain practitioners from electronic prescription requirement. Effective date.
SB27 amends Oklahoma’s controlled dangerous substances prescription law to refine when electronic prescribing is required and when practitioners may use non-electronic prescriptions instead. The bill keeps the general rule that Schedule II drugs, and most Schedule III, IV, and V controlled substances, must be prescribed electronically, but it expands and clarifies a list of exemptions. Those exemptions include veterinarians, temporary technology or power failures, direct dispensing by a practitioner, certain hospital- and facility-based orders, hospice-related prescriptions, prescriptions for drugs dispensed from pharmacies on federal property, prescriptions covered by a licensing-board waiver or extension, short-duration supplies, urgent situations where a patient’s condition is at risk, and practitioners who work exclusively in medically underserved areas.
The bill also requires practitioners using an exception to document it in the patient’s medical record, and in some cases to use official prescription forms approved by the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control. It directs licensing boards to share information with the Bureau for enforcement purposes, and it adds or updates rules governing registration, issuance, cancellation, return, and security of official prescription forms. The bill preserves existing limits on refills and time periods for Schedule III, IV, and V prescriptions, and it retains the prohibition on mailing controlled substances except in narrow circumstances. The act would take effect November 1, 2025.
SB27 would amend 63 O.S. 2021, Section 2-309, the state statute governing prescriptions for controlled dangerous substances. Its main legal effect is to broaden and clarify exceptions to Oklahoma’s electronic prescribing mandate while adding documentation and enforcement requirements tied to those exceptions. The bill affects practitioners, pharmacists, licensing boards, the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control, and patients receiving controlled substance prescriptions, especially in rural, hospice, hospital, veterinary, and other special-care settings.
The available record shows no committee transcript or recorded votes, so there is no direct evidence of debate or opposition in the provided materials. Based on the bill text and caption, the measure appears to be framed as a technical and access-oriented adjustment to the state’s electronic prescribing rules rather than a major policy reversal. The inclusion of multiple exemptions suggests an effort to accommodate clinical and operational realities while maintaining the overall electronic-prescribing framework.
The likely points of contention are the scope of the new exemptions and the safeguards attached to them. Supporters would likely favor flexibility for veterinarians, hospice care, medically underserved areas, emergency situations, and facilities where electronic prescribing may be impractical, while critics could be concerned that broader exceptions weaken diversion controls and make enforcement harder. Another possible issue is the exclusion of practitioners with prior disciplinary action related to controlled substances from the medically underserved area exemption, which may be seen as necessary oversight by some and overly restrictive by others.